Cargando…

A79 THE RELATIONSHIP BETWEEN VISCERAL ADIPOSITY AND NONALCOHOLIC FATTY LIVER DISEASE DIAGNOSED BY CONTROLLED ATTENUATION PARAMETER IN PEOPLE WITH HIV: A PILOT STUDY

BACKGROUND: Aging people with HIV (PWH) on antiretroviral therapy face high rates of metabolic dysfunction and nonalcoholic fatty liver disease (NAFLD). Fat alterations are frequent in PWH and predict worse cardiometabolic outcomes. Visceral adipose tissue (VAT) is an important compartment of body f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elgretli, W, Paisible, N, Costiniuk, C, Cox, J, Kablawi, D, Klein, M, Kronfli, N, Routy, J -P, Falutz, J, Lebouche, B, Guaraldi, G, Sebastiani, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991350/ http://dx.doi.org/10.1093/jcag/gwac036.079

Ejemplares similares

The Relationship between Visceral Adiposity and Nonalcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter in People with HIV: A Pilot Study
por: Sebastiani, Giada, et al.
Publicado: (2022)

Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort
por: Cinque, Felice, et al.
Publicado: (2023)

A43 SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD)
por: Kablawi, D, et al.
Publicado: (2023)

Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact
por: Elgretli, Wesal, et al.
Publicado: (2023)

Concurrent HIV viral blips during two episodes of multicentric Castleman disease in an adult on antiretroviral therapy: Implication for HIV persistence
por: Darwish, Ilyse, et al.
Publicado: (2021)

Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection
por: Benmassaoud, Amine, et al.
Publicado: (2018)

A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

A34 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028) †
por: Mboumba Bouassa, Ralph-Sydney, et al.
Publicado: (2022)

Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study
por: Costiniuk, CT, et al.
Publicado: (2019)

P15-02. Participation in immune-based therapy trial excludes participation in future trials: solving this problem
por: Routy, J, et al.
Publicado: (2009)

Influence of letermovir treatment on gut inflammation in people living with HIV on antiretroviral therapy: protocol of the open-label controlled randomised CIAO study
por: Royston, Léna, et al.
Publicado: (2023)

Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients
por: Sebastiani, Giada, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases
por: Kablawi, Dana, et al.
Publicado: (2023)

Cholic Acid Enhances Visceral Adiposity, Atherosclerosis and Nonalcoholic Fatty Liver Disease in Microminipigs
por: Yamada, Sohsuke, et al.
Publicado: (2017)

A type II implementation-effectiveness hybrid quasi-experimental pilot study of a clinical intervention to re-engage people living with HIV into care, ‘Lost & Found’: an implementation science protocol
por: Cox, Joseph, et al.
Publicado: (2020)

Nasal Nitric Oxide Levels in HIV Infection: A Cross-Sectional Study
por: Costiniuk, Cecilia T., et al.
Publicado: (2018)

Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial
por: Houghton, David, et al.
Publicado: (2017)

Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease
por: Chung, Goh Eun, et al.
Publicado: (2023)

Experiences of Migrant People Living with HIV in a Multidisciplinary HIV Care Setting with Rapid B/F/TAF Initiation and Cost-Covered Treatment: The ‘ASAP’ Study
por: Arora, Anish K., et al.
Publicado: (2022)

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028—study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation
por: Costiniuk, Cecilia T, et al.
Publicado: (2019)

Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study
por: Lanièce Delaunay, Charlotte, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease is associated with both subcutaneous and visceral adiposity: A cross-sectional study
por: Kure, Takeshi, et al.
Publicado: (2019)

The Importance of Visceral Adipose Tissue Detected by Imaging Methods to Assess Nonalcoholic Fatty Liver Disease Properly
por: Ozcelik, Fatih, et al.
Publicado: (2021)

Associations Between Abdominal Obesity Indices and Nonalcoholic Fatty Liver Disease: Chinese Visceral Adiposity Index
por: Chen, Xueyu, et al.
Publicado: (2022)

Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report
por: Costiniuk, Cecilia T., et al.
Publicado: (2018)

The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection
por: Mehraj, Vikram, et al.
Publicado: (2016)

Nonalcoholic fatty liver disease in obese adolescent females is associated with multi-tissue insulin resistance and visceral adiposity markers
por: Cree-Green, Melanie, et al.
Publicado: (2019)

T Regulatory Cells in the Visceral Adipose Tissues
por: Fooks, Allen N., et al.
Publicado: (2021)

Visceral Adipose Tissue Area as an Independent Risk Factor for Elevated Liver Enzyme in Nonalcoholic Fatty Liver Disease
por: Chung, Goh Eun, et al.
Publicado: (2015)

Increased reengagement of out-of-care HIV patients using Lost & Found, a clinic-based intervention
por: Linthwaite, Blake, et al.
Publicado: (2022)

Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032)
por: Isnard, Stéphane, et al.
Publicado: (2022)

Visceral adiposity syndrome
por: Lopes, Heno F., et al.
Publicado: (2016)

Delayed linkage to HIV care among asylum seekers in Quebec, Canada
por: Kronfli, Nadine, et al.
Publicado: (2019)

Frailty in older people living with HIV: current status and clinical management
por: Kehler, D. Scott, et al.
Publicado: (2022)

Visceral Adipose Tissue Area as an Independent Risk Factor for Elevated Liver Enzyme in Nonalcoholic Fatty Liver Disease: Erratum
Publicado: (2015)

Lipids in the Wrong Place: Visceral Fat and Nonalcoholic Steatohepatitis
por: Perseghin, Gianluca
Publicado: (2011)

Subcutaneous adipose tissue & visceral adipose tissue
por: Mittal, Balraj
Publicado: (2019)

Visceral Adiposity Index: An Indicator of Adipose Tissue Dysfunction
por: Amato, Marco Calogero, et al.
Publicado: (2014)

The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research
por: Mehraj, Vikram, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_12ngcsct5ut4mg8hdgt2b0ol6j